Cantor Fitzgerald Maintains Overweight on Reata Pharmaceuticals, Raises Price Target to $145
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan maintains an Overweight rating on Reata Pharmaceuticals (NASDAQ:RETA) and raises the price target from $110 to $145.
July 24, 2023 | 1:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Reata Pharmaceuticals' price target has been raised from $110 to $145 by Cantor Fitzgerald, maintaining an Overweight rating.
The raised price target indicates the analyst's increased confidence in the company's future performance. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100